Heterojunction-driven MXenzyme biocatalysis: a progressive strategy to remodel tumor immune microenvironments for improved therapeutic efficacy

and metal-polyphenol encapsulation, we constructed a robust nanoplatform for synergistic photothermal/enzymatic/immunotherapy. This system effectively catalyzes the generation of a cytotoxic ROS storm within tumor cells, while its catalase-like activity alleviates tumor hypoxia and augments type-II photodynamic therapy. Subsequently, the induced ICD, together with the released TLR7/8 agonist R848, promotes dendritic cell maturation and enhances T-cell infiltration, ultimately reversing the immunosuppressive TME. This work provides a promising strategy for TME reprogramming and demonstrates significant antitumor efficacy in triple-negative breast cancer, highlighting its broad potential in advancing cancer immunotherapy.